Artiva Biotherapeutics, Inc. ARTV Temporary Equity Par Or Stated Value Per Share

Temporary Equity Par Or Stated Value Per Share at other companies

Prospect CapitalPSEC

$0.000.0%

FCR

FutureCrest Acquisition FCRS

$28.75M—

Prospect CapitalPSEC

70.2M-1.3%

FCR

FutureCrest Acquisition FCRS

$10.10—

Perella Weinberg PartnersPWP

$17.47-5.6%

FIP

FTAI Infrastructure Inc.FIP

19.5%—

Other financials

Income statement

See full

Revenue-—

Operating income-$24.4M-10.2%

Net income-$23.5M-15.8%

EPS (diluted)-$0.95-14.5%

Balance sheet

See full

Cash & equivalents$21.4M-30.6%

Total debt$10.3M-26.7%

Total equity$87.8M-48.0%

Total assets$106.0M-44.6%

Cash flow

See full

Operating cash flow-$21.0M-5.6%

CapEx$242.0K-52.6%

Free cash flow-$21.2M-4.1%

Valuation

See full

Market cap$429.03M+1,015%

Enterprise value$417.88M+1,832%

Profitability

See full

Operating margin-83.9%—

Net margin-79.3%—

Returns & leverage

See full

Return on equity-67.9%—

Debt / equity0.1×0.0×

Current ratio8.2×-5.8×

Where this comes from

Reported directly by Artiva Biotherapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:TemporaryEquityParOrStatedValuePerShare.

The official record: Artiva Biotherapeutics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Artiva Biotherapeutics, Inc.'s temporary equity par or stated value per share.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Artiva Biotherapeutics, Inc.'s temporary equity par or stated value per share?: Artiva Biotherapeutics, Inc. (ARTV) reported temporary equity par or stated value per share of $0.00 in Q3 2024.